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Abstract
Background: Although screening for maternal red blood cell antibodies during pregnancy is a standard procedure, the
prevalence and clinical consequences of non-anti-D immunization are poorly understood. The objective was to create a
national database of maternal antibody screening results that can be linked with population health registers to create a
research resource for investigating these issues.
Study Design and Methods: Each birth in the Swedish Medical Birth Register was uniquely identified and linked to the text
stored in routine maternal antibody screening records in the time window from 9 months prior to 2 weeks after the delivery
date. These text records were subjected to a computerized search for specific antibodies using regular expressions. To
illustrate the research potential of the resulting database, selected antibody prevalence rates are presented as tables and
figures, and the complete data (from more than 60 specific antibodies) presented as online moving graphical displays.
Results: More than one million (1,191,761) births with valid screening information from 1982–2002 constitute the study
population. Computerized coverage of screening increased steadily over time and varied by region as electronic records
were adopted. To ensure data quality, we restricted analysis to birth records in areas and years with a sustained coverage of
at least 80%, representing 920,903 births from 572,626 mothers in 17 of the 24 counties in Sweden. During the study period,
non-anti-D and anti-D antibodies occurred in 76.8/10,000 and 14.1/10,000 pregnancies respectively, with marked differences
between specific antibodies over time.
Conclusion: This work demonstrates the feasibility of creating a nationally representative research database from the
routine maternal antibody screening records from an extended calendar period. By linkage with population registers of
maternal and child health, such data are a valuable resource for addressing important clinical questions, such as the
etiological significance of non-anti-D antibodies.
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Introduction
The screening of pregnant women for the presence of red blood
cell (RBC) antibodies is a standard prenatal procedure in
developed countries. The primary purpose of this screening is
the prevention of hemolytic disease of the fetus and newborn
(HDFN), which can result from maternal RBC antibodies crossing
the placental barrier into fetal circulation and attacking fetal RBCs
[1]. Anti-rhesus D (or simply, anti-D) antibody has long been
recognized to be responsible for most cases of HDFN [2]. Due to
screening for anti-D and associated immunoprophylactic measures
implemented since the 1970’s in Europe and the U.S., the
prevalence of anti-D antibodies in pregnant women has decreased
from approximately 10% in RhD negative women to a current
level of 0.1 to 2%, depending on whether routine antenatal Rh-
prophylaxis is used [3]. In addition to anti-D antibody, there are
more than 50 antibodies reported to be associated with HDFN [4].
Some of these RBC antibodies, such as anti-c and anti-K, can
cause severe disease in the fetus or newborn, while others such as
anti-C, -E, -e, -Fya, -Fyb, -Jka, Jkb, -M, -N, -S, and -s are
considered to be non-aggressive but nonetheless are carefully
monitored. Others such as anti-Lea, -Leb, -P1, and -A1 are
considered clinically insignificant.
Despite widespread routine screening for maternal antibodies in
recent decades and the use of electronic databases for managing
the screening program and laboratory results, there has been no
effort to our knowledge to construct national databases from these
data for research purposes. In contrast to other areas of health
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ized population registers are used to study national trends, studies
of alloimmunization during pregnancy typically represent a
limited geographical area and/or time period [5–7].The focus of
published work has been anti-D immunization and the associated
prophylaxis routines that have resulted in a significant reduction in
HDFN. Research into the distribution, determinants and clinical
consequences of non-anti-D RBC antibodies has been hampered
by the lack of large population databases, as these antibodies have
low prevalence and thus require a study population larger than
what is typically available. However, as anti-D antibody
prevalence declines, these non-anti-D maternal antibodies are
associated with an increasing proportion of cases of erythrocyte
immunization and HDFN and warrant careful studies of their
prevalence and potential risks for fetal and newborn health. The
objective of our work was to investigate the feasibility of
constructing a national research database for addressing such
questions using the computerized routine maternal screening
records of an entire population over an extended calendar period.
This manuscript describes the compilation of a database from
the routine blood typing and antibody screening results for over
one million pregnancies in Sweden. We illustrate the research
potential of such data by presenting the time trends in nationwide
prevalence rates of various RBC antibodies over a 20-year
calendar period.
Methods
Ethics Statement
This research was approved by the Stockholm Regional Ethics
committee (Diary number 2008/672-32). Informed consent was
not obtained since all personal information was made anonymous
to investigators prior to analysis in accordance with Swedish law.
Swedish maternal screening program
For a majority of pregnant women in Sweden, ABO/RhD
typing and RBC antibody screening of serum or plasma samples
occur at the first prenatal appointment between the 8th and 10th
weeks. In recent years, most RhD positive women without
irregular antibodies are screened just once, while RhD negative
women are retested at the 25th and 35th weeks. For positive
antibody screening test results, laboratory identification of the
antibodies and quantification of antibody titers is subsequently
performed at the regional blood centers. Because prenatal care in
Sweden is provided at no cost for all women, compliance with
screening guidelines is expected to be high.
The technology used for antibody screening has changed over
time. In the early years of this study the maternal antibody
screening was done using a manual indirect antiglobulin test (IAT)
in tubes and against enzyme treated RBC. From the mid-1980’s,
low ionic strength solution (LISS) was used as the RBC suspension
medium, replacing phosphate buffered saline. In 1989–1990,
gelcard technology was introduced in the country. From 1993–
1994, enzyme screening as first line screening was abandoned,
leaving gel IAT as the routine screening method in most
laboratories. Procedures with solid phase techniques were
introduced from the mid-1990s and fully automated systems with
microcolumn technology were introduced from around 2000.
Data sources
Maternal antibody screening records were extracted from the
Scandinavian Donations and Transfusions (SCANDAT) database
which contains records on blood donation, transfusion, and
laboratory tests for any person who was registered in any of the
regional blood center databases in Sweden since 1968. SCAN-
DAT has been described in detail elsewhere [8]. Briefly,
computerized data were obtained from all regional blood centers
in Sweden and used to create a relational database, where the
individuals were linked to national population and health registers
using their unique ten-digit national identity number. Following
confidentiality requirements, the cleaned and validated data were
permanently de-identified by replacing each person’s national
identity number with a random study number.
The Swedish Medical Birth Register (SMBR) contains data on
all births in Sweden since 1973, including mother’s age, country of
birth, county of residence and parity, and delivery and infant
details including singleton and multiple births and stillbirths, infant
sex, and neonatal diagnoses coded using the ICD classification
system. The Swedish Medical Birth Register includes 98–99% of
all births in Sweden and the quality of the data is high [9]. At the
time of de-identification of the SCANDAT database, it included
records from the SMBR from 1st January 1982 through 31st
December 2002.
Data Extraction
The unit of analysis in this manuscript is a birth – each
individual infant born, whether in a single or multiple delivery,
and including live births and still births. Each birth was uniquely
identified based on mother’s study number, date of birth, parity,
and birth order. For each birth in the SMBR from 1982–2002,
maternal antibody screening records were extracted from
SCANDAT in the time window from 9 months prior to 2 weeks
after the delivery date.
Because laboratory results were stored in free text format, a
computerized search was undertaken for text corresponding to
specific antibodies. Since a woman must first screen positive with a
non-specific test in order to be subjected to testing for specific
antibodies, these text data are confirmatory tests for the presence
of antibodies, thereby reducing the likelihood of a false positive test
result. The search list of antibodies was compiled by examining the
more structured text data and from published reports of known
antibodies. The computerized search used regular expressions, a
flexible software means of identifying and extracting specified text
patterns that has been used to perform automated informatics
tasks with free-text clinical records [10]. Since our data were
stored as an Oracle database, we used POSIX regular expression
syntax. The regular expressions accounted for differences in
notation, capitalisation, spacing and use of punctuation marks (see
Table S1).
Validation. To validate the accuracy and completeness of the
computerized search, we visually examined all the text information
from a sample of 2374 laboratory records, representing all
pregnancy-related screening and antibody tests for 200 randomly
chosen pregnancies, 100 of which were selected at random from
those defined as antibody positive by our computer code and 100
selected from those defined as negative. Using this subsample, our
validation calculated three measures of the performance of the
automated search algorithm: positive predictive value (PPV) for
women identified as antibody positive; negative predictive value
(NPV) for women identified as antibody negative; and antibody
identification accuracy of the antibodies in women who were truly
antibody positive. For all 200 women, human examination verified
that the computerized search had correctly classified whether or
not any antibodies were present, yielding a PPV and NPV of
100%. Thus based on a Binomial distribution, an approximate
95% confidence interval for the PPV and NPV of our search
algorithm is (0, 3%). Among the 100 positive women, one specific
antibody was missed and one misspelled laboratory result entry
Maternal Antibody Screening Database
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would have resulted in a false negative and false positive test
respectively if these were the only specific antibodies present. The
100 antibody positive women had 108 specific antibody terms
found by the search algorithm, of which 107 were verified. Thus
the accuracy of the algorithm in recognizing specific antibody
search terms within our validation subsample is 0.99 (95%
confidence interval: 0.95, 1.00).
Illustrative data analysis and visualization
To illustrate the research potential of the database, we present
selected antibody prevalences in this manuscript as tables and
figures, and the complete data (from more than 60 specific
antibodies) are available online as moving graphical displays,
which are becoming a prominent and effective tool for data
presentation [11].
Software
All data preparation steps used SAS version 9.2 (SAS Institute,
Cary, NC, USA) and its SQL capabilities. Software for data
visualization and analysis included SAS, R (R Foundation for
Statistical Computing, Vienna, Austria; www-r-project.org) and
the Motion Chart application from Google (Google Visualization
API, Mountain View, CA, USA).
Results
Definition of the study population
The database contains information on 1,936,608 birth events
occurring from 1982–2002. After data cleaning and removal of
records with invalid identifiers, a total of 1,936,087 births from
1,029,008 individual women were available. A total of 1,191,761
births (i.e. 61.6%) could be linked with valid maternal screening
records (see Figure 1). The proportion of births with valid
screening data increased steadily over time (from 7.5% in 1982 to
77.5% in 2002) as electronic medical records became more
widespread. Regional variations in data coverage were largely
attributable to different dates of introduction of computerization
(see Figure 2). Coverage rates in some centres were also affected
by technical or administrative issues: for example, data from
several laboratories were excluded because of systematically
missing laboratory dates, while administrative difficulties prevent-
ed the acquisition of maternal screening data from some
laboratories.
A birth was deemed antibody-positive for a given antibody if the
antibody was mentioned in at least one of the maternal antibody
records associated with the birth. For anti-D antibody, a birth was
only deemed positive if the positive finding was not suspected to be
due to RhD prophylaxis (i.e., if no search terms indicating
prophylaxis administration were found).
To limit potential errors due to inconsistent data reporting
practices and to minimize any potential reporting bias in favor of
positive antibody findings, we restricted analysis to records from
women who gave birth in counties and years with a sustained data
coverage rate of at least 80%. For example, although data from
Stockholm County were available from 1982, the coverage only
reached the 80% threshold in 1987, increasing to 98–99% in
subsequent years (see Figure 2). From 1982 to 1986, only two
counties contributing 28,829 births (7.8% of the total births in the
period) were included. As more areas of Sweden reached sufficient
data coverage to be included, the proportion of total births
represented in the study sample increased to 40.2% in 1987–1991,
57.7% in 1992–1996, and 77.5% in 2002 (see Figure 2). It is worth
noting that one region of Sweden, accounting for 121,303 birth
events with antibody data, did not meet the inclusion criteria at
any time and were thus excluded from analysis. The coverage rate
for all regions included in our analysis was 93.7%.
Description of the study population
From 1 January 1982 to 31 December 2002, 920,903 births
(representing 17 of the 24 counties of Sweden and 47.6% of the
1,936,087 total valid births in the period) from 572,626 mothers
satisfied the inclusion criteria. The characteristics of these births
are summarized in Table 1. Maternal age at delivery increased
from an average of 28.0 years from 1982–1986 to 30.1 years from
1997–2002. The percentage of RhD negative women was
consistent (14–15%) across all years.
Frequency of antibodies
From 1982–2002, a total of 8,141 births (0.88% of all births
nationwide with screening information) from 6,428 women (1.1%)
were associated with at least one maternal RBC antibody. Table 2
presents antibodies that had a prevalence of at least 1 in 10,000 in
our data, and the rarer antibodies are presented as supplementary
Figure 1. Descriptive schematic of the extraction of the final
study sample.
doi:10.1371/journal.pone.0027619.g001
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and prevalences across each year are presented in Figure S1.
Similar graphical displays examined by region indicated a
stabilizing of antibody prevalences from the time a sustained
coverage of at least 80% was achieved. Rhesus system antibodies
were the most common (33.3 per 10,000 births), followed by Lewis
system (17.6/10,000), MNS system (9.4/10,000), and Kell system
antibodies (7.0/10,000). Of the 8,141 births that were antibody-
positive, 15.9% were positive for anti-D. The most frequently
occurring non-anti-D antibodies were anti-Lea (13.9/10,000),
anti-E (13.0/10,000), anti-M (8.0/10,000), and anti-K (5.8/
10,000). Multiple antibodies were detected in 877 births (10.8%
of all antibody-positive births) from 732 women. The most
frequently found combinations of antibodies are displayed in
Table 3, of which the combination of anti-C and anti-Cw was the
most frequent (1.4% of antibody-positive births), followed by anti-c
and anti-E (1.3%), anti-Lea and anti-Leb (1.1%), and anti-D and
anti-C (1.0%).
Temporal trends
Maternal RBC antibody prevalence estimates in 1982-1986 are
lower (range 39.7–69.4/10,000 births) than in subsequent years
(1987–2002: range 67.9–112.3/10,000) (Figure 3). Anti-D
antibody prevalence rates remained constant from 1987–2002,
ranging from 11.2 to 17.2/10,000 births. Non-anti-D antibody
prevalences were constant from 1987 (63.4/10,000 births) until a
sharp increase between 1990 (68.3/10,000) and 1991 (93.6/
10,000). This elevated non-anti-D antibody prevalence was
sustained until 1994 (96.6/10,000) but then decreased to fluctuate
around the 2002 rate of 65.6/10,000. Prevalence rates for the
clinically significant antibodies anti-c and anti-K remained
constant across the entire study period (overall 1982–2002 rates
of 4.5 and 5.8/10,000 births, respectively). Anti-E antibody
prevalences fluctuated from a 1987 rate of 8.3/10,000 to a 2000
rate of 16.6/10,000 for an overall 1982–2002 rate of 13.0/10,000.
Discussion
We have demonstrated the feasibility of using routine maternal
antibody screening data to establish a large population-based
research database covering over 20 years of screening activity on a
well-defined population of pregnant women. The research
potential of the database is illustrated by presenting the prevalence
rates for a large number of specific maternal antibodies over a long
calendar period. To our knowledge, this provides the first
comprehensive assessment of such a wide range of RBC antibodies
for a well-defined population, as heretofore sample sizes have been
insufficient to study antibodies with low prevalence.
The data provided a number of interesting insights into the
alloimmunization in our population. Even in the age of
prophylactic treatment with immune globulin, immunization with
anti-D antibody in pregnant women still occurs. The observed
prevalence of anti-D immunization in this nationwide cohort from
1982–2002 was 14.1/10,000 births, comparable with previous
regional estimates of 14.2/10,000 in 1980–1991 [6] and 12.6/
10,000 in 1983–1989 [12]. Although we limited our analysis to
data from regions that had achieved a sustained high coverage
rate, similar prevalence estimates were obtained from all available
data, suggesting that reporting bias is not a serious concern.
Immunization with non-anti-D antibodies was much more
common than with anti-D, occurring at over 5 times the
frequency. Interestingly, the rate of anti-D immunization was
fairly constant across the years, in contrast to the sharp increase in
Figure 2. Percentage of Swedish births from 1982–2002, stratified by geographical region, that are included in the study
population.
doi:10.1371/journal.pone.0027619.g002
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though these trends may reflect in part the changes in screening
technology during that time. The absence of information
concerning technologies used is a feature of many registers that
needs to be considered in data analysis. Where information can be
obtained from the laboratories conducting the assays, this can be
included as a potential confounder in epidemiological analysis.
Since such information is often unavailable or difficult to obtain,
the changes in sensitivity and specificity due to technical progress
are more commonly dealt with by careful statistical modeling of
calendar time (and perhaps regional) effects.
The purpose of our analysis was to illustrate the potential of
good quality data extracted from routine clinical laboratory
records for a given population, and not to generalize our findings
to other populations. Antibody prevalence rates are known to
depend on a number of population-specific factors, including
underlying antigen genotype frequencies and histories of sensiti-
zation. For example, while samples in the U.S. [13], Canada
[14,15], England [5], the Netherlands [16], and Norway [17]
report maternal anti-D prevalences that are similar to our
estimates (between 8–23/10,000 births), a Kuwaiti sample
reported a prevalence of 522/10,000, a rate that may be partially
explained by the high local fertility rate [18]. Prevalence rates are
also dependent on trends in clinical practice and screening
technologies, so that observed changes over time are at least partly
due to different routines and technologies used. For example, in
the mid-1980’s LISS/IAT replaced saline IAT as the screening
method in Sweden, thereby increasing the sensitivity of antibody
detection. The introduction of the gel card technology in the early
1990’s increased the sensitivity for many clinically significant
antibodies (e.g., Rhesus antibodies, Kidd antibodies and Duffy
antibodies) while fewer Lewis antibodies were detected. When
enzyme screening was abandoned in 1994, unspecific reactions,
often reported as unspecified antibodies, decreased.
The database described in this manuscript is constructed from
the available data in the SCANDAT donation and transfusion
database. Due to ethical requirements, the SCANDAT database
was anonymised after compilation and it was thus not possible to
perform further linkages to the routine maternal screening data
that accumulated since 2002. However, the construction of our
maternal RBC antibody database was a ‘‘proof of principle’’
exercise whose feasibility provides important support for future
data linkages to all available population screening records.
For the period 1982–2002, our database represents a large
proportion of all births in Sweden, although there are a number of
shortcomings. As mentioned previously, administrative difficulties
prevented the acquisition of data from several centers of
sufficiently high quality to merit inclusion in the present study.
In addition, data entry practices differ by laboratory and over time
so that not all laboratory results were computerized in a fashion
that was usable (e.g., missing sample identifiers and laboratory test
dates). The highlighting of quality control issues is an important
Table 1. Characteristics of births in Sweden included in maternal red blood cell antibody prevalence rates, 1982–2002.
Characteristic 1982–1986 1987–1991 1992–1996 1997–2002 Overall, 1982–2002
Births, N 28,829 205,809 303,975 382,290 920,903
Individual women, N 23,673 164,287 244,412 301,342 572,626*
Maternal age (years) at delivery,
mean (SD)
28.5 (5.1) 28.9 (5.1) 29.3 (5.0) 30.1 (5.0) 29.5 (5.1)
Maternal RhD bloodgroup, %
births
RhD+ 85.1 84.5 85.1 85.2 85.0
A+ 39.7 38.5 38.6 38.2 38.5
B+ 10.0 9.9 10.1 10.3 10.2
AB+ 4.7 4.7 4.6 4.5 4.6
O+ 30.7 31.3 31.8 32.2 31.8
RhD2 14.8 14.5 14.6 14.6 14.6
A2 6.8 6.7 6.8 6.7 6.7
B2 1.7 1.6 1.6 1.7 1.6
AB2 0.8 0.8 0.8 0.8 0.8
O2 5.4 5.3 5.4 5.5 5.4
Unknown 0.1 1.0 0.2 0.1 0.4
Parity, mean 1.9 1.9 2.0 1.9 1.9
Male child, % 51.3 51.3 51.2 51.4 51.3
Mother’s country of birth, %
births
Sweden 86.6 84.2 84.3 82.5 83.6
Other Nordic country 7.6 6.2 3.9 2.4 3.9
Other country 5.6 9.6 11.8 15.1 12.5
Unknown 0.3 0.1 0.1 0.1 0.1
*Note: Because an individual woman can give birth in more than one time period, the number of women overall from 1982–2002 does not equal the row total.
doi:10.1371/journal.pone.0027619.t001
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source data and in turn the quality of data obtained from future
linkages.
The volume of maternal antibody records in the database and
the storage of this information as free text required the
computerized extraction of data similar to previous investigations
of blood bank data for central Sweden [6]. The performance of
these automated approaches is dependent on the capabilities of the
extraction method as well as the structure and consistency of the
free text records. The computerized search process yielded very
high agreement with human abstraction in a validation sample of
over 2000 records for 200 pregnant women, with high PPV, NPV
and accuracy in identifying antibodies. PPV and NPV for
nonspecific antibody status are important due to the increased
monitoring for women who test positive for any antibody
(regardless of the antibody). Similarly, identification accuracy is
important to ensure that specific antibodies which can have
different medical consequences are correctly reflected in the
database. A limitation of the current version of the database is that
only the presence or absence of antibodies is characterized: titer
information is present for some records but the lack of a consistent
data structure presents a challenge in extracting this information.
Table 2. Maternal red blood cell antibodies with a prevalence of at least 1 in10,000 in 920,903 births in Sweden from 1982–2002.
Per 10,000 births
Overall Percent of
1982–1986 1987–1991 1992–1996 1997–2002 1982–2002 Count Ab+ births
Any antibody 53.1 81.4 102.3 83.8 88.4 8141 100
Non-anti-D antibodies 41.3 70.6 90.6 71.9 76.8 7072 86.9
Rh system 18.4 28.9 36.8 33.9 33.3 3063 37.6
anti-D 12.1 12.3 14.8 14.6 14.1 1296 15.9
anti-E 2.8 10.7 15.7 12.9 13 1198 14.7
anti-C 0.4 3.5 4.9 5.1 4.5 418 5.1
anti-c 1 3.9 4.9 4.7 4.5 411 5
anti-Cw 0 1.8 1.9 2.1 1.9 174 2.1
Lewis system 26.4 23.8 19.7 11.8 17.6 1616 19.9
anti-Lea 19.8 19.1 15.7 9.3 13.9 1283 15.8
anti-Leb 6.6 6 5.5 3.2 4.7 435 5.3
MNS system 0.7 4.4 9.4 12.7 9.3 861 10.6
anti-M 0.7 3.6 8.2 10.8 8 738 9.1
Kell system 4.2 6.9 6.7 7.5 7 644 7.9
anti-K 4.2 6.3 6.2 5.4 5.8 534 6.6
P system 0 3.9 6.6 3.6 4.6 420 5.2
anti-P1 0 3.9 6.6 3.5 4.5 415 5.1
Duffy system 0 1.9 2.6 2.2 2.2 205 2.5
anti-Fya 0 1.8 2.4 2.1 2 189 2.3
Kidd system 0.7 1.4 1.9 2.7 2.1 191 2.4
anti-Jka 0.7 1.3 1.7 2.2 1.8 165 2
Lutheran system 0.4 0.9 0.6 1.5 1.1 97 1.2
anti-Lua 0.4 0.9 0.6 1.5 1 95 1.2
Other
Unspecified antibodies 0.4 4.2 10.7 3.7 6.0 554 6.8
anti-A1 0.7 2.9 2.8 1.8 2.4 217 2.7
anti-Bg 0 1 3 3.1 2.5 229 2.8
doi:10.1371/journal.pone.0027619.t002
Table 3. Most frequently occurring combinations of maternal
red blood cell antibodies in 920,903 births in Sweden from
1982–2002: total number of births and percentage of
antibody-positive births.
Antibody combination Count Percent of Ab+ births
Anti-C, Anti-Cw 116 1.4
Anti-E, Anti-c 105 1.3
Anti-Lea, Anti-Leb 93 1.1
Anti-D, Anti-C 82 1.0
Anti-D, Anti-E 38 0.5
Anti-D, Anti-C, Anti-E 36 0.4
Anti-C, Anti-e 17 0.2
Anti-K, Anti-E 16 0.2
doi:10.1371/journal.pone.0027619.t003
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first step in investigating a number of important research questions.
By linkage with population registers of maternal and child health,
clinically relevant questions can be investigated, such as identifica-
tion of risk factors and important confounders (notably history of
transfusion) for immunization; etiological significance of various
antibodies for fetal and pediatric outcomes including stillbirth,
prematurity, infant death, hyperbilirubinemia, and anemia. In
particular, investigation of the clinical relevance of non anti-D
antibodies has the potential to inform policies for the management
of pregnant women with these antibodies: the current recommen-
dation of the American College of Obstetricians and Gynecologists
istofollowthe samecare guidelinesasforRhesusalloimmunization,
although there is limited evidence to support this practice [19,20].
In addition, linkage with other population registers would enable
the study of associations between RBC antibodies and subsequent
health outcomes in women such as hospitalizations, overall
mortality, cancer and immune disorders.
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